What is GHRP-2?
GHRP-2 (growth hormone-releasing peptide-2) is a synthetic hexapeptide that acts as an agonist of the ghrelin receptor (GHS-R1a), a G-protein coupled receptor found on somatotroph cells and throughout the hypothalamus. Developed in the 1990s, GHRP-2 is one of the most potent and widely used ghrelin mimetics in research and clinical settings, capable of triggering robust growth hormone secretion within minutes of administration. Unlike GHRH analogues that directly stimulate the pituitary, GHRP-2 works primarily through somatostatin inhibition and GHRH amplification, making it mechanistically distinct and highly synergistic with GHRH peptides.
Mechanism of Action
GHRP-2 binds to the ghrelin receptor (GHS-R1a) on hypothalamic GH-releasing hormone (GHRH) neurons and directly on anterior pituitary somatotrophs. This dual action produces a rapid, potent GH release. At the hypothalamic level, GHRP-2 stimulates GHRH neurons while simultaneously suppressing somatostatin (GH inhibitor) release, creating a powerful synergistic effect. At the pituitary level, GHRP-2 sensitizes somatotrophs to endogenous GHRH, amplifying pituitary GH secretion beyond what either stimulus produces alone.
Peak GH levels typically occur within 30–60 minutes of subcutaneous or intramuscular injection. GHRP-2 also exhibits non-GH axis effects: it stimulates prolactin and ACTH, resulting in modest elevation of cortisol and prolactin—side effects that distinguish it from other ghrelin mimetics like Ipamorelin, which suppresses these hormones.
Research & Studies
Bowers et al. (1996) in Endocrinology first characterized GHRP-2's mechanism, demonstrating that it acts as a potent GH secretagogue independent of GHRH availability and that it is synergistic when combined with GHRH. Subsequent studies confirmed GHRP-2's efficacy across diverse populations. Ghigo et al. (2002) in a comprehensive review showed that GHRP-2 produces GH release in healthy adults, GH-deficient patients, and the elderly, with response magnitude often exceeding that of GHRH alone.
Cordido et al. (1999) compared GHRP-2 to other GH secretagogues and found it among the most potent, with GH peaks 2–3× baseline after a single injection. Studies also documented GHRP-2's effects on prolactin and cortisol: Coy et al. (1992) found that unlike Ipamorelin, GHRP-2 stimulates prolactin and cortisol, which can be problematic with frequent dosing.
Common Uses
- Growth hormone deficiency: Clinical and research use to stimulate endogenous GH production
- Body recomposition: Enhanced lean mass gain and fat loss when stacked with GHRH analogues
- Muscle protein synthesis: GH synergy with resistance training for hypertrophy
- Bone density: GH-mediated osteogenic stimulation, particularly in aging populations
- Acute GH pulse testing: Used in clinical diagnostics to assess pituitary GH reserve
- Recovery optimization: Post-workout peptide injection to amplify GH-mediated recovery
Dosing & Protocol
Standard dosing: GHRP-2 is administered via subcutaneous or intramuscular injection, typically 100–200 mcg (0.1–0.2 mg) per dose. Higher doses (300–600 mcg) are used in some protocols but do not produce proportionally greater GH release due to receptor saturation.
Frequency: Single daily dose (often in morning), multiple daily doses (2–3× daily spaced 4–6 hours apart), or post-workout injection (immediately after training for GH-recovery synergy). Frequent dosing (3× daily) risks cumulative prolactin and cortisol elevation.
Half-life: ~7–10 minutes (very short), necessitating frequent dosing for sustained GH elevation or combination with longer-acting GHRH analogues.
Cycle length: 8–12 weeks on, 2–4 weeks off to minimize tachyphylaxis and hormonal downregulation. Continuous use beyond 12 weeks may reduce receptor sensitivity and GH response.
Synergies
GHRP-2 is maximally synergistic with GHRH analogues—specifically Sermorelin, Tesamorelin, or CJC-1295. The GHRH + GHRP-2 stack produces GH peaks 2–3× higher than either peptide alone, with a longer-sustained GH elevation. This is the most potent oral GH secretion stack available.
GHRP-2 also synergizes with Ipamorelin (another ghrelin mimetic with different side effect profile) for sustained GH elevation throughout the day, though the combination redundantly activates the ghrelin receptor and offers diminishing returns compared to GHRP-2 + GHRH.
For body recomposition, GHRP-2 + GHRH stacks pair excellently with Tesamorelin (visceral fat reduction), Semaglutide (appetite/metabolic control), or AOD-9604 (tissue-specific fat loss).
Receptor Overlaps & Avoidance
Critical: Do NOT stack GHRP-2 with GHRP-6. Both are ghrelin receptor agonists that bind the same GHS-R1a receptor; combining them causes receptor saturation, reduced GH output, and redundant prolactin/cortisol elevation with no synergistic benefit.
Do NOT combine two GHRH analogues (e.g., GHRP-2 + Sermorelin + CJC-1295 simultaneously)—GHRHR receptor saturation limits benefit.
GHRP-2 is NOT recommended for individuals sensitive to cortisol elevation (athletes prone to muscle catabolism, individuals with anxiety/HPA-axis sensitivity, or those prone to carpal tunnel). Ipamorelin is a superior choice for these populations due to minimal cortisol and prolactin effects.
Safety Profile
GHRP-2 is generally well-tolerated but has more hormonal side effects than other GH secretagogues:
- Prolactin elevation: Modest elevation (1.5–2× baseline); usually asymptomatic but can cause gynecomastia with extended use or high frequency
- Cortisol elevation: Acute spike post-injection; chronic elevation with frequent dosing may impair sleep and immune function
- Appetite stimulation: GHRP-2 activates hunger circuits (ghrelin-mimetic effect), potentially problematic for individuals in caloric deficit
- Water retention: Mild fluid retention from GH elevation; typically resolves post-cycle
- Carpal tunnel syndrome: Rare but possible with chronic GH elevation; reversible upon discontinuation
- Injection site reactions: Mild erythema or induration
- Sleep disruption: If injected in evening, cortisol spike may impair sleep initiation
To mitigate cortisol effects, GHRP-2 is best dosed in the morning (cortisol naturally high) rather than evening, and used on a cycling protocol (8–12 weeks on, 2–4 weeks off) rather than continuously. Pairing with an anti-cortisol supplement (phosphatidylserine, magnesium, or adaptogenic herbs) may reduce side effects.